Search bioRxiv⌕ Search

Biology subjects

Neal, L.

Publications and source records attributed to Neal, L..

2 recordsLinked to original sources
bioRxiv2026

Accounting for DNA Recovery and Cell Culturability Enhances Quantitative Compatibility of Molecular and Legiolert Assays for Legionella pneumophila

Disagreement between molecular and culture-based assays for Legionella pneumophila detection is widely reported, yet comparisons have largely been based on direct assay-derived concentrations or binary positive/negative outcomes. However, it remains unclear whether molecular-culture disagreement reflects concentration-level incompatibility or unaccounted methodological and physiological differences related to DNA recovery and cell culturability. In this study, we also observed disagreement between molecular and Legiolert assays in source and finished drinking water samples collected from eight full-scale drinking water systems across the United States. Molecular thresholds adjusted for DNA recovery and cell culturability only partially resolved these discrepancies. We therefore developed a probabilistic Monte Carlo framework that incorporates sample-specific DNA recovery and cell culturability to evaluate the quantitative consistency of culturable L. pneumophila concentrations estimated by molecular and Legiolert assays. Quantitatively consistent and inconsistent samples occurred across both binary concordant and discordant classifications, demonstrating that positive/negative agreement poorly reflects concentration-level comparability. Overall, molecular and Legiolert assays showed strong quantitative consistency once sample-specific DNA recovery and cell culturability were considered. A small proportion of persistent inconsistencies at specific sampling sites, coupled with atypical microbial indicators, suggest that sample heterogeneity likely contributed to the remaining discrepancies. These findings demonstrate that integrating DNA recovery and cell culturability enhanced quantitative consistency between molecular and Legiolert assays and supports the use of molecular methods as rapid quantitative tools to complement culture-based L. pneumophila monitoring. SynopsisAccounting for DNA recovery and cell culturability revealed broad quantitative compatibility between molecular and Legiolert assays for Legionella pneumophila in drinking water. TOC O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=88 SRC="FIGDIR/small/739452v2_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@1e01cdcorg.highwire.dtl.DTLVardef@86bbc2org.highwire.dtl.DTLVardef@190fc66org.highwire.dtl.DTLVardef@1aa9ec8_HPS_FORMAT_FIGEXP M_FIG C_FIG

microbiology↗
bioRxiv2017

PI3Kδ inhibition supports memory T cells with enhanced antitumor fitness

Phosphatidylinositol-3-kinase p110{delta} (PI3K{delta}) inhibition by Idelalisib (CAL-101) in hematological malignancies directly induces apoptosis in cancer cells and disrupts immunological tolerance by depleting regulatory T cells (Tregs). Yet, little is known about the direct impact of PI3K{delta} blockade on effector T cells from CAL-101 therapy. Herein, we demonstrate a direct effect of p110{delta} inactivation via CAL-101 on murine and human CD8+ T cells that promotes a strong undifferentiated memory phenotype (elevated CD62L/CCR7, CD127 and Tcf7). These CAL-101 T cells also persisted longer after transfer and exerted stronger antitumor immunity compared to traditionally expanded CD8+ T cells in two solid tumor models. Thus, this report describes a novel direct enhancement of CD8+ T cell memory by a p110{delta} inhibitor that leads to markedly improved tumor regression. This finding has significant implications to improve outcomes from next generation cancer immunotherapies.\n\nHighlightsO_LIIn vitro blockade of PI3K p110{delta} with CAL-101 endows antitumor T cells with a stronger memory phenotype than those treated with AKTi\nC_LIO_LIThe strong memory phenotype of CAL-101 treated cells translates into improved survival of mice bearing aggressive tumors after adoptive transfer of these T cells\nC_LIO_LIHuman CAR engineered T cells treated with CAL-101 possess an enhanced memory phenotype and robust antitumor efficacy\nC_LIO_LIThe antitumor efficacy of CAL-101 primed T cells is not mediated by high CD62L or CD127 expression, but is likely driven by their stem memory phenotype\nC_LI\n\neTOC BlurbBowers et al report a novel function of PI3K blockade using the p110{delta} subunit inhibitor CAL-101 to induce memory and antitumor potency in CD8+ T cells. Ex vivo treatment of T cells with CAL-101 leads to improved antitumor control and subject survival in both murine transgenic T cell and human CAR T cell models.

cancer biology↗